Aethlon Medical, Inc. (NASDAQ: AEMD) disclosed that a pre‑clinical study published in the bioRxiv pre‑print archive on November 20, 2025 demonstrates the company’s Galanthus nivalis agglutinin (GNA) affinity resin can bind and remove extracellular vesicles (EVs) from plasma samples of patients with Long COVID, while simultaneously depleting seven microRNAs linked to the JAK‑STAT inflammatory pathway.
The study, conducted in partnership with the University of California, San Francisco’s Long COVID clinic, shows the Hemopurifier can capture both large (100–500 nm) and small (40–200 nm) EVs. The seven microRNAs that were removed are known to drive chronic inflammation in Long COVID, and their depletion suggests the device could reduce the inflammatory milieu that underlies many of the condition’s persistent symptoms.
For Aethlon, the data open a new therapeutic avenue beyond its current oncology focus. The Hemopurifier already holds FDA Breakthrough Device designation for advanced cancer and life‑threatening viral infections, and the Long COVID findings could accelerate regulatory discussions for an additional indication, broaden partnership opportunities, and ultimately diversify the company’s revenue streams.
Aethlon’s financial profile remains challenging: the company has posted negative earnings and operating margins in recent quarters, yet it maintains a solid cash position and no debt. The pre‑clinical results therefore represent a potential upside that could offset the company’s current earnings weakness and provide a foundation for future clinical development and commercialization.
CEO Jim Frakes said, “While oncology remains our primary focus, these data reinforce the Hemopurifier’s broader platform potential and may open new avenues for partnership or regulatory development in autoimmune and viral indications.” Chief Medical Officer Steven P. LaRosa added, “The study demonstrates for the first time that the GNA affinity resin removes EVs in Long COVID samples and depletes microRNAs associated with the JAK‑STAT pathway, a therapeutic target in current Long COVID trials.”
The announcement was well received by investors, reflecting optimism about the Hemopurifier’s potential to address a large unmet medical need and to expand the company’s product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.